25061944|t|Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model.
25061944|a|Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disorder of motor neurons causing progressive muscle weakness, paralysis, and eventual death from respiratory failure. There is currently no cure or effective treatment for ALS. Besides motor neuron degeneration, ALS is associated with impaired energy metabolism, which is pathophysiologically linked to mitochondrial dysfunction and glutamate excitotoxicity. The Deanna Protocol (DP) is a metabolic therapy that has been reported to alleviate symptoms in patients with ALS. In this study we hypothesized that alternative fuels in the form of TCA cycle intermediates, specifically arginine-alpha-ketoglutarate (AAKG), the main ingredient of the DP, and the ketogenic diet (KD), would increase motor function and survival in a mouse model of ALS (SOD1-G93A). ALS mice were fed standard rodent diet (SD), KD, or either diets containing a metabolic therapy of the primary ingredients of the DP consisting of AAKG, gamma-aminobutyric acid, Coenzyme Q10, and medium chain triglyceride high in caprylic triglyceride. Assessment of ALS-like pathology was performed using a pre-defined criteria for neurological score, accelerated rotarod test, paw grip endurance test, and grip strength test. Blood glucose, blood beta-hydroxybutyrate, and body weight were also monitored. SD+DP-fed mice exhibited improved neurological score from age 116 to 136 days compared to control mice. KD-fed mice exhibited better motor performance on all motor function tests at 15 and 16 weeks of age compared to controls. SD+DP and KD+DP therapies significantly extended survival time of SOD1-G93A mice by 7.5% (p = 0.001) and 4.2% (p = 0.006), respectively. Sixty-three percent of mice in the KD+DP and 72.7% of the SD+DP group lived past 125 days, while only 9% of the control animals survived past that point. Targeting energy metabolism with metabolic therapy produces a therapeutic effect in ALS mice which may prolong survival and quality of life in ALS patients. 
25061944	23	38	Deanna Protocol	Chemical	-
25061944	106	135	amyotrophic lateral sclerosis	Disease	MESH:D000690
25061944	137	140	ALS	Disease	MESH:D000690
25061944	142	147	mouse	Species	10090
25061944	155	184	Amyotrophic Lateral Sclerosis	Disease	MESH:D000690
25061944	186	189	ALS	Disease	MESH:D000690
25061944	206	226	Lou Gehrig's disease	Disease	MESH:D000690
25061944	233	259	neurodegenerative disorder	Disease	MESH:D019636
25061944	297	312	muscle weakness	Disease	MESH:D018908
25061944	314	323	paralysis	Disease	MESH:D010243
25061944	349	368	respiratory failure	Disease	MESH:D012131
25061944	424	427	ALS	Disease	MESH:D000690
25061944	437	462	motor neuron degeneration	Disease	MESH:D009410
25061944	464	467	ALS	Disease	MESH:D000690
25061944	487	513	impaired energy metabolism	Disease	MESH:D008659
25061944	555	580	mitochondrial dysfunction	Disease	MESH:D028361
25061944	585	594	glutamate	Disease	MESH:C537425
25061944	595	609	excitotoxicity	Disease	
25061944	615	630	Deanna Protocol	Chemical	-
25061944	707	715	patients	Species	9606
25061944	721	724	ALS	Disease	MESH:D000690
25061944	794	797	TCA	Chemical	MESH:D014238
25061944	832	860	arginine-alpha-ketoglutarate	Chemical	-
25061944	862	866	AAKG	Chemical	-
25061944	977	982	mouse	Species	10090
25061944	992	995	ALS	Disease	MESH:D000690
25061944	997	1001	SOD1	Gene	20655
25061944	1002	1006	G93A	DNAMutation	tmVar:c|SUB|G|93|A;HGVS:c.93G>A;VariantGroup:0;OriginalGene:20655;CorrespondingGene:6647;CorrespondingSpecies:10090
25061944	1009	1012	ALS	Disease	MESH:D000690
25061944	1013	1017	mice	Species	10090
25061944	1156	1160	AAKG	Chemical	-
25061944	1162	1185	gamma-aminobutyric acid	Chemical	MESH:D005680
25061944	1187	1199	Coenzyme Q10	Chemical	MESH:C024989
25061944	1218	1230	triglyceride	Chemical	MESH:D014280
25061944	1239	1260	caprylic triglyceride	Chemical	MESH:C003637
25061944	1276	1279	ALS	Disease	MESH:D000690
25061944	1437	1450	Blood glucose	Chemical	MESH:D001786
25061944	1458	1478	beta-hydroxybutyrate	Chemical	MESH:D020155
25061944	1527	1531	mice	Species	10090
25061944	1615	1619	mice	Species	10090
25061944	1628	1632	mice	Species	10090
25061944	1810	1814	SOD1	Gene	20655
25061944	1815	1819	G93A	DNAMutation	tmVar:c|SUB|G|93|A;HGVS:c.93G>A;VariantGroup:0;OriginalGene:20655;CorrespondingGene:6647;CorrespondingSpecies:10090
25061944	1820	1824	mice	Species	10090
25061944	1904	1908	mice	Species	10090
25061944	2119	2122	ALS	Disease	MESH:D000690
25061944	2123	2127	mice	Species	10090
25061944	2178	2181	ALS	Disease	MESH:D000690
25061944	2182	2190	patients	Species	9606
25061944	Association	HGVS:c.93G>A;CorrespondingGene:6647	MESH:D000690
25061944	Negative_Correlation	MESH:C024989	MESH:D000690
25061944	Association	MESH:D000690	6647

